Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
15 authors.
Trent A GombergDepartment of Cellular & Molecular Medicine, University of California San Diego, La Jolla, CA, USA.ORCID 0000-0002-0600-2301
Sara ElmsaouriDepartment of Cellular & Molecular Medicine, University of California San Diego, La Jolla, CA, USA.ORCID 0000-0002-6928-756X
Hema M KopalleDepartment of Cellular & Molecular Medicine, University of California San Diego, La Jolla, CA, USA.ORCID 0000-0002-1872-7318
Michael W BaughnDepartment of Cellular & Molecular Medicine, University of California San Diego, La Jolla, CA, USA.ORCID 0000-0001-8525-8024
Melinda S BeccariDepartment of Cellular & Molecular Medicine, University of California San Diego, La Jolla, CA, USA.ORCID 0000-0003-1019-6388
Melissa McAlonis-DownesDepartment of Cellular & Molecular Medicine, University of California San Diego, La Jolla, CA, USA.ORCID 0000-0002-8152-2075
Jonathan W ArtatesDepartment of Cellular & Molecular Medicine, University of California San Diego, La Jolla, CA, USA.
Deepak PantDepartment of Cellular & Molecular Medicine, University of California San Diego, La Jolla, CA, USA.ORCID 0000-0001-5627-3380
Harriet MakCapstan Therapeutics, San Diego, CA, USA.
Aaron A SmargonDepartment of Cellular & Molecular Medicine, University of California San Diego, La Jolla, CA, USA.ORCID 0000-0002-4677-1682
Tynan C SanderDepartment of Cellular & Molecular Medicine, University of California San Diego, La Jolla, CA, USA.ORCID 0009-0004-2257-8804
Esaul GarciaChemical Engineering Department, University of California San Diego, La Jolla, CA, USA.
Dominic P LeeDepartment of Cellular & Molecular Medicine, University of California San Diego, La Jolla, CA, USA.ORCID 0000-0001-6880-453X
Don W ClevelandDepartment of Cellular & Molecular Medicine, University of California San Diego, La Jolla, CA, USA.ORCID 0000-0002-1934-3682
Gene W YeoDepartment of Cellular & Molecular Medicine, University of California San Diego, La Jolla, CA, USA.ORCID 0000-0002-0799-6037
Funding
Viral Vector Core (VVC)P30CA014195 · NCI · SALK INSTITUTE FOR BIOLOGICAL STUDIES · PI Alan Saghatelian · 1985 to 2026
$82.8M
Functional RNA elements in the human genomeR01HG004659 · NHGRI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Kevin Daniel Corbett, Eugene Wei-Ming Yeo · 2008 to 2026
$12.4M
Therapeutic strategies for microsatellite expansion diseases using RNA-targeting CRISPR/CasR01NS103172 · NINDS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI MAURICE SCOTT SWANSON, Eugene Wei-Ming Yeo · 2017 to 2026
$5.6M
UC San Diego Genetics Training ProgramT32GM145427 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI BRUCE A HAMILTON · 2022 to 2026
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder caused by the selective deterioration of motor neurons in the central nervous system (CNS). A key driver of this pathogenesis is nuclear loss of ALS-associated protein TDP-43, leading to mis-splicing of TDP-43 targets including important neuronal genes
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Dual-targeting snRNA gene therapy rescues STMN2 and UNC13A splicing in TDP-43 proteinopathies. · full record | OpenQuestion